PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 61 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 6.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,961,196 | 0.0% | 2,273,894 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $12,961,196 | -8.1% | 2,273,894 | -2.7% | 0.01% | -14.3% |
| Q4 2022 | $14,109,102 | -99.9% | 2,335,944 | -2.8% | 0.01% | -22.2% |
| Q3 2022 | $15,881,153,000 | +25.7% | 2,402,595 | -0.7% | 0.01% | +28.6% |
| Q2 2022 | $12,635,151,000 | -24.4% | 2,420,527 | -0.1% | 0.01% | 0.0% |
| Q1 2022 | $16,714,056,000 | -11.3% | 2,422,327 | +60.0% | 0.01% | 0.0% |
| Q4 2021 | $18,845,391,000 | -59.3% | 1,513,686 | +2.0% | 0.01% | -63.2% |
| Q3 2021 | $46,353,719,000 | +25.7% | 1,483,319 | +15.2% | 0.02% | +18.8% |
| Q2 2021 | $36,867,853,000 | +32.3% | 1,287,735 | +100.3% | 0.02% | +33.3% |
| Q1 2021 | $27,860,280,000 | -24.5% | 642,979 | +24.6% | 0.01% | -29.4% |
| Q4 2020 | $36,921,875,000 | +68.7% | 516,029 | -29.0% | 0.02% | +41.7% |
| Q3 2020 | $21,888,330,000 | – | 726,463 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 15,594,877 | $1,115,813,000 | 9.76% |
| Baker Brothers Advisors | 10,118,636 | $723,988,000 | 2.73% |
| Rock Springs Capital Management LP | 360,363 | $25,784,000 | 0.55% |
| HHLR ADVISORS, LTD. | 750,000 | $53,663,000 | 0.43% |
| Old Well Partners, LLC | 3,450 | $247,000 | 0.13% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 111,065 | $7,947,000 | 0.11% |
| PERSONAL CFO SOLUTIONS, LLC | 4,500 | $322,000 | 0.08% |
| ARS Investment Partners, LLC | 7,400 | $529,000 | 0.06% |
| CAAS CAPITAL MANAGEMENT LP | 50,000 | $3,578,000 | 0.03% |
| FMR LLC | 4,209,963 | $296,295,000 | 0.03% |